行情

LPCN

LPCN

Lipocine
NASDAQ

实时行情|Nasdaq Last Sale

0.9956
+0.0156
+1.59%
盘后: 0.9011 -0.0945 -9.49% 19:59 01/14 EST
开盘
0.9900
昨收
0.9800
最高
1.000
最低
0.9303
成交量
85.63万
成交额
--
52周最高
2.420
52周最低
0.9303
市值
8,790.22万
市盈率(TTM)
-4.5091
分时
5日
1月
3月
1年
5年
Brief-Lipocine Inc- 1 月 14 日,收到来自纳斯达克的通知,表明该公司不再遵守纳斯达克上市规则
reuters.com · 2天前
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 01/06 13:24
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has been selected for podium presentation and three abstracts have been selected for poster presentatio...
PR Newswire · 01/05 13:00
Dosing underway in Lipocine's mid-stage LPCN 1148 study for liver cirrhosis
Lipocine (NASDAQ:LPCN) announces that the first patient has been dosed in its Phase 2 proof-of-concept clinical study for the management of liver cirrhosis. Shares down 2.8% premarket at $1.06. The primary endpoint
Seekingalpha · 2021/12/22 14:05
BRIEF-Lipocine Announces Patient Dosed In Its Phase 2 Study With LPCN 1148 For Management Of Liver Cirrhosis
reuters.com · 2021/12/22 13:18
LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS
Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the management of ...
PR Newswire · 2021/12/22 13:00
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 2021/11/19 14:04
LPCN: Third Quarter Update
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT
Benzinga · 2021/11/16 14:20
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解LPCN最新的财务预测,通过LPCN每股收益,每股净资产,每股现金流等数据分析Lipocine近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测LPCN价格均价为3.750,最高价位6.00,最低价为2.500。
最高6.00
均价3.750
最低2.500
现价0.9956
EPS
实际EPS
预期EPS
-0.06-0.05-0.03-0.02
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 57
机构持股: 948.72万
持股比例: 10.75%
总股本: 8,829.07万
类型机构数股数
增持
11
56.30万
建仓
7
21.72万
减持
7
62.95万
平仓
2
9.13万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.51%
制药与医学研究
+0.11%
高管信息
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Financial Officer/Executive Vice President
Morgan Brown
Vice President
Nachiappan Chidambaram
Lead Director/Independent Director
Stephen Hill
Director
John Higuchi
Independent Director
Jeffrey Fink
Independent Director
Richard Ono
暂无数据
LPCN 简况
Lipocine Inc是一家临床阶段的生物制药公司。该公司专注于将其口服给药技术应用于代谢和内分泌疾病药物的开发。该公司的候选产品组合旨在产生药代动力(PK)特性,并促进降低给药要求,在某些情况下绕过首次通过代谢,减少副作用,并消除限制生物利用度的胃肠道相互作用。该公司的主要候选产品TLANDO是一种口服睾酮替代疗法(TRT),由十一酸睾酮(TU)组成。该公司的候选候选产品包括LPCN 1144,这是一种口服生物相同睾酮前体药物,由TU组成,用于治疗非肝硬化非酒精性脂肪性肝炎(NASH),目前正在进行II期试验,以及TLANDO XR,这是一种口服TRT产品,由三碳酸睾酮(TT)组成,已完成II期试验。

微牛提供Lipocine Inc(NASDAQ-LPCN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的LPCN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LPCN股票基本功能。